

GOLD Sponsors (3.000 Euro each)

BAUSCH+LOMB
See better. Live better.

meise GmbH
MEDIZINTECHNIK

Therakos
ECP Immunomodulation

URSAPHARM
Arzneimittel GmbH

SILVER Sponsors (1.500 Euro each)

Bristol Myers Squibb

neovii

NOVARTIS

OmniVision
Freude am Sehen

Pierre Fabre
Innovative Oncology

Santen

BRONZE Sponsors (800 Euro each)

easy-look

OCULUS

espansione group

Théa
let's open our eyes

This meeting is also supported by

Renate Angermann
Stiftung (5.000 Euro)



SFB 1607 Immunmodulierende und
anti(lymph)angiogene Therapien bei altersbezogenen
erblindenden Augenerkrankungen (1.000 Euro)

Organizers:

Philipp Steven
Competence Center for ocular GVHD,
Department of Internal Medicine I, University Hospital Cologne
Department of Ophthalmology, University Hospital Cologne

Christof Scheid
Cell Therapy Unit,
Department of Internal Medicine I,
University Hospital Cologne



March 8-9, 2024

INTERNATIONAL
EXPERT MEETING ON
**OCULAR GRAFT-VS-HOST
DISEASE**

Center for Integrated Oncology,
Cologne, Germany



**UNIKLINIK
KÖLN**



Centrum für Integrierte Onkologie
Aachen Bonn Köln Düsseldorf

PROGRAM

INTERNATIONAL EXPERT MEETING

THURSDAY, MARCH 7TH

Individual arrival

FRIDAY, MARCH 8TH

| | |
|-------------|---|
| 8.15 | Welcome address: <i>Claus Cursiefen, Michael Hallek, Christof Scheid</i> |
| 8.30-8.45 | Opening remarks day 1: <i>Philipp Steven</i> |
| 8.45-10.30 | Session 1: Pathogenesis and risk factors of ocular GVHD, Chairs: <i>Yoko Ogawa and Victor Perez</i> <ol style="list-style-type: none">1. Development of ocular GVHD – Victor Perez, Miami2. Animal models in ocular GVHD – Ajay Sharma, Irvine3. Fibrosis in ocular GVHD – Yoko Ogawa, Tokyo4. Risk factors of ocular GVHD – Martina Maaß, Cologne |
| 10.30-10.45 | Coffee break |
| 10.45-12.15 | Session 2: Diagnosis and grading of ocular GVHD, Chairs: <i>Margarita Calonge and Tina Dietrich-Ntoukas</i> <ol style="list-style-type: none">1. Current grading schemes for ocular GVHD – Tina Dietrich-Ntoukas, Berlin2. Proposal for early diagnosis of ocular GVHD – Giulia Coco, Rome3. Biomarkers – Margarita Calonge, Valladolid |
| 12.15-13.15 | Lunch Break |

| | |
|-------------|--|
| 13.15-14.00 | Keynote lecture: Why are many patients getting GVHD and some don't? – <i>Daniel Wolff, Regensburg</i> |
| 14.00-15.30 | Session 3: Novel targets and (preventive) therapies, Chairs: <i>Sandeep Jain and Daniel Wolff</i> <ol style="list-style-type: none">1. Stratification of chronic GVHD – Daniel Wolff, Regensburg2. Preventive therapies for ocular GVHD – Leonie Menghesha, Cologne3. Pooled Human Globulins – Sandeep Jain, Chicago4. Regenerative topical therapies – Volkan Tahmaz, Cologne |
| 15.30-15.45 | Coffee break |
| 15.45-17.15 | Session 4: Translational science: other organs and the eye, Chairs: <i>Michael E. Stern and Giulio Ferrari</i> <ol style="list-style-type: none">1. Manifestation of systemic immunity in the eye – Michael E. Stern, Irvine/Cologne2. Angiogenesis in acute and chronic GVHD – Katarina Riesner, Berlin3. Skin GVHD – Mirjana Ziemer, Leipzig4. Neuroinflammation in ocular surface diseases: relevance in oGVHD – Giulio Ferrari, Milan |
| 17.20-18.00 | Roundtable discussion, Moderators: <i>Christof Scheid and Philipp Steven</i> <ul style="list-style-type: none">· How can we better translate basic research into the clinic?· How could we attract more ophthalmologists to GVHD care? |

SATURDAY, MARCH 9TH

| | |
|-------------|--|
| 8.30 | Opening remarks day 2: <i>Christof Scheid</i> |
| 8.45-10.15 | Session 5: Patient-centered care, Chairs: <i>Kathleen Kunert and Udo Holtick</i> <ol style="list-style-type: none">1. My Story: The ocular GVHD patient2. Rehabilitation of patients with severe ocular surface disease – Kathleen Kunert, Masserberg3. AI and digital solutions to manage complications following cellular therapy – Guido Kobbe, Duesseldorf4. Optimizing peri- and post-transplant care – Udo Holtick, Cologne |
| 10.15-10.30 | Coffee break |
| 10.30-12.00 | Session 6: Novel concepts in allogeneic transplantation and cellular therapy, Chairs: <i>Daniel Wolff and Christof Scheid</i> <ol style="list-style-type: none">1. Immunotherapy and allogeneic transplantation in ALL – Max Krämer, Cologne2. Refractory lymphoma: CART or transplantation or both – Nadine Kutsch, Cologne3. Beyond transplantation: immunotherapy in myeloma – Tim Richardson, Cologne4. Cellular therapy for viral complications – Christof Scheid, Cologne |
| 12.00-12.30 | Wrap up: What's new, what have we learned. |
| 12.30 | Farewell comments – <i>Philipp Steven and Christof Scheid</i> |